Applications will be open from 1 July 2021 at 9 am ACST and be closed at 30 July 2021 at 4 pm ACST.

Photo by Nathan Anderson on Unsplash.

Minimum Data closes at 5:00 pm (ACT Local Time) on 23 February 2022

Minimum Data closes at 5:00 pm (ACT Local Time) on 20 April 2022

Minimum Data closes at 5:00 pm (ACT Local Time) on 16 February 2022

Minimum Data closes at 5:00 pm (ACT Local Time) on 9 Feb 2022

Minimum Data closes at 5:00 pm (ACT Local Time) on Wednesday 02 February 2022.

Minimum Data closes at 5:00 pm (ACT Local Time) on Wednesday 2 February 2022.

Minimum data due 1700 ACT local time, 24 November 2021.

Minimum Data closes at 5:00 pm (ACT Local Time) on 9 February 2022.

Minimum Data closes at 5:00 pm (ACT Local Time) on 9 February 2022.

Minimum Data closes at 5:00 pm (ACT Local Time) on 25 Jan 2022.

An information session will be held on Tuesday 12 October, registration can be made here.

Minimum Data closes at 5:00 pm (ACT Local Time) on 16 February 2022.

Minimum Data closes at 5:00 pm (ACT Local Time) on 2 February 2022.

Minimum Data Dates: 

Round 1: 5pm ACT local time on 25 August 2021

Round 2: 5pm ACT local time on 2 February 2022

Expressions of interest close 19 April 2021.

Minimum Data: 5pm ACT local time on 7 July 2021

 Expressions of interest are open and will need to be submitted by 17th December 2021 by 5pm by email to hcffoundation@hcf.com.au

Expressions of interest close 10 March 2021

Strategic investment in data registries, biobanks and data linkage platforms for primary health care in a range of settings. 

• Maternal health 
• Early childhood, or 
• Exercise and nutrition.

Projects should aim to improve medicine use and medicine intervention by pharmacists in primary health and transitions of care.

• Stream 1-Cancer in children
• Stream 2-Cancer in adolescents

Clinical trial in Australia, in collaboration with international counterparts. 

Stream 1: utilise existing evidence to develop or improve approaches for the early diagnosis of ovarian cancer, cancers of the pancreas, liver cancer or lung cancer that have a clinically feasible pathway to implementation

Stream 2: enable approaches for the early diagnosis of cancers with unknown primary site that have a clinically feasible pathway to implementation. 

Development of novel interventions, including therapeutics and devices, to prevent cardiovascular disease and stroke; develop novel treatments and devices to improve outcomes; and conduct small-scale development projects to establish feasible, evidence-based approaches aimed at improving survivorship and reducing morbidity.

$17.5 million across 4 streams.